NYSE:CRLLife Sciences
Charles River (CRL) Trims 2026 Outlook After Divestitures and Leadership Changes Is The Strategy Working?
In February 2026, Charles River Laboratories International reported fourth-quarter and full-year 2025 results showing slightly lower revenue of US$994.23 million for the quarter and US$4.02 billion for the year, a net loss driven in part by US$210.97 million of intangible asset impairments and US$165 million of goodwill impairments, and issued 2026 guidance calling for at least flat to 1.5% reported revenue growth and GAAP EPS of US$6.30 to US$6.80.
Soon after, the company adjusted its 2026...